Amyloid peptide and tau proteins, the main histological hallmarks of Alzheimer’s disease, have been widely used as biomarkers of anti-amyloid and anti-tau drugs. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.